Expression of CD43 in human microglia and its downregulation in Alzheimer's disease

A Matsuo1, D G Walker, K Terai

  • 1Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, Canada.

Insights

CD43 expression is lower in Alzheimer disease microglia compared to normal brains. This suggests CD43 may play an anti-adhesional role in resting microglia, with cleavage occurring during activation.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • CD43 (leukosialin, sialophorin) is a transmembrane protein expressed on various immune cells.
  • Microglia are the resident immune cells of the brain and play critical roles in neuroinflammation.
  • Alzheimer disease (AD) is characterized by neuroinflammation and microglial activation.

Purpose of the Study:

  • To investigate the expression of CD43 in the brain tissue of neurologically normal individuals and patients with Alzheimer disease.
  • To compare CD43 expression levels in microglia between normal and AD brains.
  • To explore the potential role of CD43 in microglial activation and function.

Main Methods:

  • Immunohistochemical analysis of brain tissue from normal and AD cases.
  • Detection and quantification of CD43 immunoreactivity in microglia and other brain cells.
  • Comparison of CD43 expression with HLA-DR, a marker of microglial activation.

Main Results:

  • Abundant CD43 immunoreactivity was observed in ramified microglia of normal brain tissue.
  • CD43 expression was markedly lower in microglia from AD brains compared to control brains.
  • In contrast to CD43, HLA-DR expression was significantly upregulated in AD microglia, indicating activation.

Conclusions:

  • CD43 is expressed at higher levels in resting or ramified microglia compared to activated microglia.
  • This finding suggests CD43 may have an anti-adhesional role in microglia, with its expression decreasing upon activation.
  • CD43 represents a novel microglial marker associated with the resting state, offering insights into microglial dynamics in neurodegenerative diseases.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...